AsclepiX Therapeutics has filed a notice of an exempt offering of securities to raise $12,544,498.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, AsclepiX Therapeutics is raising up to $12,544,498.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Robert Dempsey played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About AsclepiX Therapeutics
AsclepiX Therapeutics is a clinical-stage biopharmaceutical company leveraging computational biology from Johns Hopkins to identify and develop peptides for improved treatments of retinal diseases. Our lead candidate, AXT107, inhibits pro-angiogenic vascular endothelial growth factor receptor 2 (VEGFR2) and activates the vessel stabilizing receptor tyrosine kinase (Tie2), the two validated pathways for the treatment of retinal vascular diseases.
To learn more about AsclepiX Therapeutics, visit http://www.asclepix.com/
Contact:
Robert Dempsey, Chief Executive Officer
610-212-1217
https://www.linkedin.com/in/robert-j-dempsey/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.